#ASH18: Can Am­gen break through the BC­MA CAR-T line and take a BiTE of the mul­ti­ple myelo­ma mar­ket? It won't be quick or easy

Am­gen’s R&D group has been fo­cus­ing con­sid­er­able at­ten­tion on its de­vel­op­ment of AMG 420 — a bis­pe­cif­ic T-cell en­gager, or BiTE, in brand name par­lance — that it be­lieves can point them to a com­pet­i­tive po­si­tion with the BC­MA CAR-Ts now an­gling for first-mover ad­van­tage, and like­ly bet­ter than an an­ti­body-drug con­ju­gate. They came to San Diego with a first look at the Phase I da­ta that in­clude a high rate of re­sponse for one dose that could cap­ture some sup­port.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER